The Milbank Memorial Fund is an endowed operating foundation that publishes The Milbank Quarterly, commissions projects, and convenes state health policy decision makers on issues they identify as important to population health.
We focus on a number of topic areas identified by state health policy leaders as important to population health.
The Center for Evidence-based Policy at Oregon Health & Science University is a national leader in evidence-based decision making and policy design.
Keep up with news and updates from the Milbank Memorial Fund. Get the latest from thought leaders, including Christopher F. Koller, president of the Fund.
We publish The Milbank Quarterly, as well as reports and issues briefs on topics important to population health.
December 2008 (Volume 86)
December 2008 | Richard L. Kravitz, Naihua Duan, Edmund J. Niedzinski, M. Cameron Hay, Saskia K. Subramanian, Thomas S. Weisner | Featured Article
Context: When feasible, randomized, blinded single-patient (n-of-1) trials are uniquely capable of establishing the best treatment in an individual patient. Despite early enthusiasm, by the turn of the twenty-first century, few academic centers were conducting n-of-1 trials on a regular basis.
Methods: The authors reviewed the literature and conducted in-depth telephone interviews with leaders in the n-of-1 trial movement.
Findings: N-of-1 trials can improve care by increasing therapeutic precision. However, they have not been widely adopted, in part because physicians do not sufficiently value the reduction in uncertainty they yield weighed against the inconvenience they impose. Limited evidence suggests that patients may be receptive to n-of-1 trials once they understand the benefits.
Conclusions: N-of-1 trials offer a unique opportunity to individualize clinical care and enrich clinical research. While ongoing changes in drug discovery, manufacture, and marketing may ultimately spur pharmaceutical makers and health care payers to support n-of-1 trials, at present the most promising resuscitation strategy is stripping n-of-1 trials to their essentials and marketing them directly to patients. In order to optimize statistical inference from these trials, empirical Bayes methods can be used to combine individual patient data with aggregate data from comparable patients.
Author(s): Richard L. Kravitz; Naihua Duan; Edmund J. Niedzinski; M. Cameron Hay; Saskia K. Subramanian; Thomas S. Weisner
Keywords: n-of-1 trial; Bayesian methods; treatment effects heterogeneity; clinical effectiveness; research policy; personalized medicine
Download the study
Read on Wiley Online Library
Read on JSTOR
Volume 86, Issue 4 (pages 533–555)
Published in 2008
The Relative Merits of Population-Based and Targeted Prevention Strategies
In This Issue